Published papers by Peter Svensson
1. List of 20 selected papers
1.
Dahlbäck B, Carlsson M, Svensson PJ
Familial thrombophilia due to a previously unrecognized mechanism characterized by poor
anticoagulant response to activated protein C: Prediction of a cofactor to activated protein C.
Proc Natl Acad Sci USA 1993;90:1004-8.
2.
Svensson PJ, Dahlbäck B
Resistance to activated protein C as a basis for venous thrombosis.
N Engl J Med 1994;330:517-22.
3.
Lindblad B, Svensson PJ, Dahlbäck B
Arterial and venous thromboembolism with fatal outcome and resistance to activated protein C.
Lancet 1994;343:917.
4.
Svensson PJ, Zöller B, Dahlbäck B
Evaluation of original and modified APC-resistance tests in unselected outpatients with clinically
suspected thrombosis and in healthy controls.
Thromb Haemostas 1997;77:332-335.
5.
Svensson PJ, Zöller B, Mattiasson I, Dahlbäck B
The factor VR506Q mutation causing APC resistance is highly prevalent amongst unselected
outpatients with clinically suspected deep venous thrombosis.
J Int Med 1997;241:379-85.
6.
Svensson PJ, Benoni G, Fredin H, Björgell O, Nilsson P,
Hedlund U, Nylander G, Bergqvist D, Dahlbäck B
Female gender and resistance to activated protein C (FV R506Q) as potential risk factors for
thrombosis after elective hip arthroplasty.
Thromb Haemost 1997;78:993-96.
7.
Björgell O, Nilsson PE, Nilsson JÅ, Svensson PJ
Location and extent of deep vein thrombosis in patients with and without protein FV:R 506Q
mutation.
Thromb Haemost 2000:83:648-51.
(This paper has been commented in Lancet 2000:356:182-3 by H. Bounameaux).
8.
Ekberg H, Svensson PJ, Simanaitis M, Dahlbäck B
Factor V R506Q mutation (activated protein C resistance) is an additional risk factor for early renal
graft loss associated with acute vascular rejection.
Transplantation 2000; 69:1577-81.
9.
Kunz G, Öhlin AK, Adami A, Zöller B, Svensson P, Lane DA
Naturally occurring mutations in the thrombomodulin gene leading to impaired expression and
2016-02-17
1 (8)
function. Blood 2002;99(10):3646-53.
10.
11.
Vossen CY, Conard J, Fontcuberta J, Makris M, van der Meer FJM, Pabinger I, Palareti G, Preston FE,
Scharrer I, Souto JC, Svensson P, Walker ID, Rosendaal FR
Hereditary thrombophilia and fetal loss: a prospective follow-up study. J Thromb Haemost
2004;2:592-6.
Själander A, Engström G, Berntorp E, Svensson P
Risk of haemorrhagic stroke in patients with oral anticoagulation compared with the general
population. J Intern Med 2003;254:434-8.
12.
Vossen CY, Conard J, Fontcuberta J, Makris M, van der Meer FJM, Pabinger I, Palareti G, Preston FE,
Scharrer I, Souto JC, Svensson P, Walker ID, Rosendaal FR
Familial thrombophilia and life-time risk of venous thrombosis.
J Thromb Haemost 2004;2:1526-32.
13.
Jonsson M, Hillarp A, Svensson P
Comparison between CoaguChek S- and Owren-type prothrombin time assay for monitoring
anticoagulant therapy. Thrombosis Research 2004;114:83-9.
14.
Vossen CY, Conard J, Fontcuberta J, Makris M, van der Meer FJM, Pabinger I, Palareti G, Preston FE,
Scharrer I, Souto JC, Svensson P, Walker ID, Rosendaal FR
Risk of a first venous thrombotic event in carriers of a familial thrombophilic defect. The European
Prospective Cohort on Thrombophilia (EPCOT).
J Thromb Haemost 2005;3(3):459-64.
15.
Elf J, Strandberg K, Svensson P
Clinical probability assessment and D-dimer determination in patients with
suspected deep vein thrombosis, a prospective multicenter management study.
Thromb Res 2009: 123(4):612-6.
16.
Själander A, Jansson J-H, Bergqvist D, Eriksson H, Carlberg B, Svensson P
Efficacy and safety of anticoagulant prophylaxis to prevent venous thromboembolism in acutely ill
medical inpatients: a meta-analysis.
J Intern Med 2008;263(1):52-60.
17.
Wieloch M, Hillarp A, Strandberg K, Svensson P
Comparison and evaluation of a Point-of-care device (CoaguChek XS) to Owren-type prothrombin
time assay for monitoring of oral anticoagulant therapy with warfarin. Thromb Res 2009 124(3):344-8.
18.
Isma N, Svensson P, Gottsäter A, Lindblad B
Prospective analysis of risk factors and distribution of venous thromboembolism in the populationbased Malmö Thrombophilia Study (MATS). Thromb Res 2009; 124(6): 663-6.
19.
Mattias Wielocha, Anders Själander, Viveka Frykman, Mårten Rosenqvist, Niclas Eriksson, Peter J
2016-02-17
2 (8)
Svensson Anticoagulation control in Sweden. Reports of time in therapeutic range (TTR), major
bleeding, and thromboembolic complications from the national quality registry AuriculA. Eur Heart J.
2011; 32(18): 2282-9.
20.
Jönsson Karl M, Wieloch Mattias1, Sterner Gunnar, Nyman Ulf, Engström Gunnar, Svensson Peter J.
Glomerular filtration rate in patients with atrial fibrillation on warfarin treatment: a subgroup analysis
from the AURICULA registry in Sweden Thrombosis Research 2011; 128: 341-345.
Editorial; Hoffman R, Brenner B. Anticoagulants and chronic kidney disease Thrombosis Research
2011; 128: 305-306
2016-02-17
3 (8)
Full list
1.
Dahlbäck B, Carlsson M, Svensson PJ
Familial thrombophilia due to a previously unrecognized mechanism characterized by poor
anticoagulant response to activated protein C: Prediction of a cofactor to activated protein C.
Proc Natl Acad Sci USA 1993;90:1004-8.
2.
Svensson PJ, Dahlbäck B
Resistance to activated protein C as a basis for venous thrombosis.
N Engl J Med 1994;330:517-22.
3.
Lindblad B, Svensson PJ, Dahlbäck B
Arterial and venous thromboembolism with fatal outcome and resistance to activated protein C.
Lancet 1994;343:917.
4.
Zöller B, Svensson PJ, He X, Dahlbäck B
Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with
inherited resistance to activated protein C.
J Clin Invest 1994; 94: 2521-24.
5.
Hellgren M, Svensson PJ, Dahlbäck B
Resistance to activated protein C as a basis for venous thromboembolism associated with pregnancy
and oral contraceptives.
Am J Obstet Gynecol 1995; 173: 210-13.
6.
Zöller B, Holm J, Svensson P, Dahlbäck B
Elevated levels of prothrombin activation fragment 1+2 in plasma from patients with heterozygous
Arg 506 to Gin mutation in the factor V gene (APC-resistance) and/or inherited protein S deficiency.
Thromb Haemostas 1996;75:270-74.
7.
Svensson PJ, Zöller B, Dahlbäck B
Evaluation of original and modified APC-resistance tests in unselected outpatients with clinically
suspected thrombosis and in healthy controls.
Thromb Haemostas 1997;77:332-335.
8.
Svensson PJ, Zöller B, Mattiasson I, Dahlbäck B
The factor VR506Q mutation causing APC resistance is highly prevalent amongst unselected
outpatients with clinically suspected deep venous thrombosis.
J Int Med 1997;241:379-85.
9.
Svensson PJ, Benoni G, Fredin H, Björgell O, Nilsson P,
Hedlund U, Nylander G, Bergqvist D, Dahlbäck B
Female gender and resistance to activated protein C (FV R506Q) as potential risk factors for
thrombosis after elective hip arthroplasty.
Thromb Haemost 1997;78:993-96.
2016-02-17
4 (8)
10. Hillarp A, Zöller B, Svensson PJ, Dahlbäck B
The 20210 A allele of the prothrombin gene is a common risk factor among Swedish outpatients
with verified deep venous thrombosis.
Thromb Haemost 1997;78:990-2.
Svensson PJ, Dahlbäck B, Marsal K
11. Lindqvist P,
506
Factor V Q mutation (activated protein C resistance) associated with reduced intrapartum blood
loss - a possible evolutionary selection mechanism.
Thromb Haemost 1998;79:69-73.
12. Zöller B, Svensson PJ, Hillarp A
The A20210 allele of the prothrombin gene is frequently associated with the factor V Arg 506 to Gln
mutation but not with protein S deficiency in thrombophilic families.
Blood 1998;91:2210-11.
13. Björgell O, Nilsson PE, Svensson P, Bergqvist D
A new scoring system for the detailed description of the distribution and thrombotic burden in deep
leg vein thrombosis.
Angiology, J Vasc Dis 1999;50:179-87.
K, Grennert L, Luterkort M, Dahlbäck B
14. Lindqvist PG, Svensson PJ, Marsál506
Activated protein C resistance (FV:Q ) and pregnancy.
Thromb Haemost 1999;81:532-7.
15. Roussos L, Florén C, Carlson J, Svensson PJ, Wallmark A, Ekberg H
Increased prevalence of apolipoprotein E3/E4 genotype among Swedish renal transplant recipients.
Nephron 1999; 83: 25-30.
16. Bergenfeldt M, Svensson PJ, Borgström A
Mesenteric vein thrombosis due to factor V Leiden gene mutation. Br J Surg 1999:86:1059-62.
17. Björgell O, Nilsson PE, Svensson PJ, Bergqvist D
A new scoring system for the detailed description of the distribution and thrombotic burden in deep
leg vein thrombosis.
Scope on Phlebology and Lymphology 1999;110-12.
18. Björgell O, Nilsson PE, Nilsson JÅ, Svensson PJ
Location and extent of deep vein thrombosis in patients with and without protein FV:R 506Q
mutation.
Thromb Haemost 2000:83:648-51.
(This paper has been commented in Lancet 2000:356:182-3 by H. Bounameaux).
19. Björgell O, Nilsson PE, Nilsson J-Å, Svensson PJ (referee: K.-G. Hinze)
Location and extent of deep vein thrombosis in patients with and without FV:R 506Q mutation.
Clin Lab 2000;46:423-4 (this paper has been selected by the editorial board for ”Journal Club
highlights”).
2016-02-17
5 (8)
20. Ekberg H, Svensson PJ, Simanaitis M, Dahlbäck B
Factor V R506Q mutation (activated protein C resistance) is an additional risk factor for early renal
graft loss associated with acute vascular rejection.
Transplantation 2000; 69:1577-81.
21. Grip O, Svensson PJ, Lindgren S
Inflammatory bowel disease promotes venous thrombosis earlier in life.
Scand J Gastroent 2000; 35:619-23.
22. Björgell O, Nilsson PE, Nilsson J-Å, Svensson PJ
On difficulties in diagnosing deep vein thrombosis in daily clinical work and research practice. Clin
Lab 2001;47:369-75.
(Editorial: Berntorp E. The clinical importance of correctly diagnosing venous thrombosis. Clin Lab
2001;47:367-68).
23. Emmerich J, Rosendaal FR, Cattaneo M, Margaglione M, De Stefano V, Cumming T, Arruda
V, Hillarp A, Reny JL, for the study group (P. Svensson) for pooled-analysis in venous
thromboembolism.
Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous
thromboembolism. Pooled analysis of 8 case-control studies including 2310 cases and 3204 controls.
Thromb Haemost 2001;86:809-16.
24. Kunz G, Öhlin AK, Adami A, Zöller B, Svensson P, Lane DA
Naturally occurring mutations in the thrombomodulin gene leading to impaired expression and
function. Blood 2002;99(10):3646-53.
25. Björkman A, Svensson PJ, Hillarp A, Burtscher IM, Rünow A, Benoni G
Factor V leiden and prothrombin gene mutation: risk factors for osteonecrosis of the femoral head in
adults. Clin Orthop Relat Res 2004;(425):168-72.
26. Vossen CY, Conard J, Fontcuberta J, Makris M, van der Meer FJM, Pabinger I, Palareti G,
Preston FE, Scharrer I, Souto JC, Svensson P, Walker ID, Rosendaal FR
Hereditary thrombophilia and fetal loss: a prospective follow-up study. J Thromb Haemost
2004;2:592-6.
27. Själander A, Engström G, Berntorp E, Svensson P
Risk of haemorrhagic stroke in patients with oral anticoagulation compared with the general
population. J Intern Med 2003;254:434-8.
28. Vossen CY, Conard J, Fontcuberta J, Makris M, van der Meer FJM, Pabinger I, Palareti G,
Preston FE, Scharrer I, Souto JC, Svensson P, Walker ID, Rosendaal FR
Familial thrombophilia and life-time risk of venous thrombosis.
J Thromb Haemost 2004;2:1526-32.
29. Björkman A, Svensson PJ, Hillarp A, Burtscher IM, Rünow A, Benoni G.
Factor V Leiden and Prothrombin Gene Mutation: Risk Factors for Osteonecrosis of the Femoral
Head in Adults. Clin Orthop 2004;425:168-72.
2016-02-17
6 (8)
30. Jonsson M, Hillarp A, Svensson P
Comparison between CoaguChek S- and Owren-type prothrombin time assay for monitoring
anticoagulant therapy. Thrombosis Research 2004;114:83-9.
31. Vossen CY, Conard J, Fontcuberta J, Makris M, van der Meer FJM, Pabinger I, Palareti G,
Preston FE, Scharrer I, Souto JC, Svensson P, Walker ID, Rosendaal FR
Risk of a first venous thrombotic event in carriers of a familial thrombophilic defect. The European
Prospective Cohort on Thrombophilia (EPCOT).
J Thromb Haemost 2005;3(3):459-64.
32. Bjorkman A, Burtscher IM, Svensson PJ, Hillarp A, Besjakov J, Benoni G
Factor V Leiden and the prothrombin 20210A gene mutation and osteonecrosis of the knee. Arch
Orthop Trauma Surg 2005;125(1):51-5.
33. Vossen CY, Walker ID, Svensson P, Souto JC, Scharrer I, Preston FE, Palareti G, Pabinger I,
van der Meer FJM, Makris M, Fontcuberta J, Conard J, Rosendaal FR
Recurrence Rate After a First Venous Thrombosis in Patients With Familial Thrombophilia.
Arterioscler Thromb Vasc Biol 2005;25(9):1992-7.
34. Strandberg K, Stenflo J, Nilsson C, Svensson PJ
APC-PCI complex concentration is higher in patients with previous venous thromboembolism Factor
V Leiden. J Thrombosis Haemost 2005;3(11):2578-80.
35. Lindqvist PG, Svensson P, Dahlbäck B
Activated protein C resistance - in the absence of factor V Leiden - and pregnancy. J Thromb
Haemost 2006;4:361-6.
36. Vossen CY, Rosendaal FR on behalf of the EPCOT study group
Risk of arterial thrombosis in carriers of familial thrombophilia.
J Thromb Haemost 2006;4(4):916-8.
37. Strandberg K, Svensson P, Öhlin A-K
Venous thromboembolism in carriers of the Factor V Leiden mutation and in patients without known
thrombophilic risk factor; prediction of recurrence and APC-PCI complex concentration and/or
soluble thrombomodulin antigen and activity. Thromb Res 2007;121(2):145-51. Epub 2007 May 11.
38. Stenflo J, Kjellberg M, Strandberg K, Svensson PJ, Kölbel T, Lindblad B
The complex between activated protein C and protein C inhibitor: A clinically useful indicator of
aortic aneurysms? Blood Cells Mol Dis 2006;36(2):118-21. Epub 2006 Feb 7.
39. Själander A, Friberg B, Svensson P, Stigendal L, Lethagen S
Menorrhagia and minor bleeding symptoms in women on oral anticoagulation.
J Thromb Thrombolysis 2007;24(1):39-41.
2016-02-17
7 (8)
40. Själander A, Jansson J-H, Bergqvist D, Eriksson H, Carlberg B, Svensson P
Efficacy and safety of anticoagulant prophylaxis to prevent venous thromboembolism in acutely ill
medical inpatients: a meta-analysis.
J Intern Med 2008;263(1):52-60.
41. Sjöberg K, Roth EB, Gustavsson L, C. Jönsson, Simán H, Henriksson G, Stenberg P, Lindblom
A, Svensson P
Autoimmune Markers in Lymphoid Malignancies. Scand J Immunol 2008;67:509-15.
42. Lindahl T, Svensson P
Självtestning och egenvård vid användning av blodproppsförebyggande läkemedel. SBU Alertrapport nr 2007-05;1-16.
43. Själander A, Jansson JH, Bergqvist D, Eriksson H, Carlberg B, Svensson P
Efficacy and safety of anticoagulant prophylaxis to prevent venous thromboembolism in acutely ill
medical inpatients: a meta-analysis. J Intern Med 2008;263(1):52-60.
44. Elf J, Strandberg K, Svensson P
Clinical probability assessment and D-dimer determination in patients with suspected deep vein
thrombosis, a prospective multicenter management study.
Thromb Res 2009: 123(4):612-6.
45. Lindahl T, Svensson P
Self-Testing and Self-Management of Oral Anticoagulation. SBU Alert report No. 2007-05;1-4.
46. Acosta S, Alhadad A, Svensson P, Ekberg O
Epidemiology, risk and prognostic factors in mesenteric venous thrombosis. Br J Surg
2008;95:1245-51.
47. Isma N, Lindblad B, Breslin T, Svensson P
The Factor V Leiden mutation is associated with a higher blood haemoglobin concentration in
women below 50 of the Malmö Thrombophilia Study (MATS)." J Thromb Thrombolysis 2008;Nov
21 [Epub ahead of print].
48. Wieloch M, Hillarp A, Strandberg K, Svensson P
Comparison and evaluation of a Point-of-care device (CoaguChek XS) to Owren-type prothrombin
time assay for monitoring of oral anticoagulant therapy with warfarin. Thromb Res 2009;
124(3):344-8.
49. Isma N, Svensson P, Gottsäter A, Lindblad B
Prospective analysis of risk factors and distribution of venous thromboembolism in the populationbased Malmö Thrombophilia Study (MATS). Thromb Res 2009; 124(6):663-6.
50. Zia E Engström G, Svensson PJ, Norrving B Pessah-Rasmussen H.
Three-year survival and stroke recurrence rates after primary intracerebral hemorrhage. Stroke
2009;40(11):3567-73.
2016-02-17
8 (8)
51. Isam N, Svensson PJ, Lindblad B, Lindqvist PG
The effect of low molecular weight heparin (dalteparin) on duration and initiation of labour. J of
Thrombosis and Thrombolysis 2009 accepted
52. Johan L Elf, Karin Strandberg, Peter J Svensson
The diagnostic performance of APC-PCI complex determination compared to D-dimer in the
diagnosis of deep vein thrombosis. Journal of Thrombosis and Thrombolysis 2010; 29(4): 465-70
53. Johan L Elf, Karin Strandberg, Peter J Svensson
Performance of two relatively new quantitative D-dimer assays ( Innovance D-dimer and
AxSYM D-dimer) for the exclusion of deep vein thrombosis
Thromb Res 2009; 124(6):701-5
54. Kuoppala M, Åkeson J, Svensson P, Lindblad B, Franzen S, Acosta S
Risk factors for haemorrhage during local intra-arterial thrombolysis for lower limb ischemia
Journal of Thrombosis and Thrombolysis 2011; 31: 226-232.
55. Nazim Isma¹, Peter J Svensson¹, Anders Gottsäter², Bengt Lindblad²
Upper extremity deep venous thrombosis in the population-based Malmö thrombophilia study
(MATS). Epidemiology, risk factors, recurrence risk, and mortality. Thromb Res 2010; 125(6):
e335-8
56. Treatment of mesenteric vein thrombosis. Bergqvist D, Svensson PJ
Semin Vasc Surg 2010; 23:65-68
57. A Cost-effectiveness Analysis of Diagnostic Algorithms of Deep
Vein Thrombosis at the Emergency Department
Jenny M. Norlin, Johan L. Elf , Peter J. Svensson , Katarina Steen Carlsson
Thromb Res 2010; 126: 195-9
58. Thrombotic Occlusion of All Left Coronary Branches in a Young Woman with Severe Ulcerative
Colitis, Carl Gunnar Gustavsson, Peter J. Svensson, Erik Hertervig, et al ISRN Cardiology, vol.
2011, Article ID 134631, 3 pages, 2011. doi:10.5402/2011/134631
a
59. Mattias Wieloch , Anders Själander, Viveka Frykman, Mårten Rosenqvist, Niclas Eriksson, Peter J
Svensson Anticoagulation control in Sweden. Reports of time in therapeutic range (TTR), major
bleeding, and thromboembolic complications from the national quality registry AuriculA. Eur Heart
J. 2011; 32(18): 2282-9.
60.
Jönsson Karl M, Wieloch Mattias1, Sterner Gunnar, Nyman Ulf, Engström Gunnar, Svensson Peter
J. Glomerular filtration rate in patients with atrial fibrillation on warfarin treatment: a subgroup
analysis from the AURICULA registry in Sweden Thrombosis Research 2011; 128: 341-345.
Editorial; Hoffman R, Brenner B. Anticoagulants and chronic kidney disease Thrombosis Research
2011; 128: 305-306
61. Mortality and inherited thrombophilia: results from the European Prospective Cohort on
Thrombophilia (EPCOT)
Ingrid Pabinger, Carla Y. Vossen, Judith Lang, Jacqueline Conard, Maria Concepción García
Dabrio, Wolfgang Miesbach, Gualtiero Palareti, Peter Svensson, Alexandra Kaider, Frits R.
Rosendaal
Journal of Thrombosis and Haemostasis 2012; 10(2); 217-22
2016-02-17
9 (8)
62. Evidence-Based Management of Anticoagulant Therapy: Antithrombotic Therapy
and Prevention of Thrombosis, 9th ed: American College of Chest Physicians
Evidence-Based Clinical Practice Guidelines
Anne Holbrook, Sam Schulman, Daniel M. Witt, Per Olav Vandvik, Jason Fish,
Michael J. Kovacs, Peter J. Svensson, David L. Veenstra, Mark Crowther, and
Gordon H. Guyatt Chest 2012;141 e152S-e184S
63. Recurrent venous thromboembolism is associated with Factor V Leiden mutation
Signy V. Sveinsdottir , Ymir Saemundsson, Nazim Isma, Anders Gottsäter, Peter J. Svensson
Accepted Thrombosis Research mars 2012
64. Triple antithrombotic therapy following an acute coronary syndrome: Prevalence, outcomes and
prognostic utility of the HAS-BLED score
J Gustav Smith, MD1; Mattias Wieloch, MD PhD1; Sasha Koul, MD1; Oscar Ö Braun, MD PhD1;
Jonathan Lumsden, MSc1; Emil Rydell, MSc1; Jenny Öhman, MD PhD1; Fredrik Scherstén, MD
PhD1; Peter J Svensson, MD PhD2 and Jesper vanderPals, MD PhD1
Accepted EuroIntervention 2012
65. Computerised assistance for warfarin dosage – Effects on treatment quality Ivar Dimberg,
Bartosz Grzymala-Lubanski,, Anette Hägerfelth, Mårten Rosenqvist, Peter Svensson, Anders
Själander
EJIM accepted 2012 August
66.
Homozygous Factor V Leiden and Compound Heterozygosity for Factor V Leiden and Prothrombin
Mutation.
Ymir Saemundsson, Signý Vala Sveinsdottir, Henrik Svantesson, Peter J Svensson J Thrombosis
and Thrombolysis accepted sept 2012 E-pub 0ct 2012
Volume 36, Issue 3 (2013), Page 324-331
67.
68.
69.
APC Resistance due to Factor V Leiden is not related to baseline inflammatory mediators or survival
up to 10 years in patients with Critical Limb Ischemia. Sampran E, Lindblad B, Gottsäter A, PJ
Svensson J Thrombosis and Thrombolysis accepted november 2012; 2013;36: 288-292
Computer aided warfarin dosing in the Swedish national quality registry AuriculA - Algorithmic
suggestions are performing better than manually changed doses.
Bartosz Grzymala-Lubanski, ; Sara Själander, ; Henrik Renlund, ; Peter J
Svensson; Anders Själander, Accepted Thrombosis Research november 2012
Socioeconomic factors and concomitant diseases are related to the risk of venous thromboembolism
during long term follow-up. Isma N, Ohlsson H, Svensson PJ, Lindblad BL, Gottsäter A J
Thrombosis and Thrombolysis 2013; 36(1) 58-64. accepted december 2012
70. Correlations between time in therapeutic range (TTR), glomerular filtration rate and
2016-02-17
10 (8)
bleeding/thromboembolic complications in patients on anticoagulant treatment with warfarin. A
report from the Swedish quality registry AuriculA., Wieloch Mattias, Jönsson Karl M , Anders
Själander, Niclas Eriksson, Svensson Peter J. Accepted Thrombosis Research 2013 january
71. Dabigatran in clinical practice – one yeat experience at Skåne University Hospital. Bergman E,
Smith J G, Wieloch M, Braun O, Svensson P J, van der Pals JAccepted Thrombosis Research 2013
and primary closure after tooth extraction in warfarin
72. Treatment with local hemostatic agents
1
treatment patients. Roger Svensson Fredrik Hallmer2Charlotta Sahlström Englesson2Peter Svensson3
Jonas Becktor; Swed Dent J 2013; 37:71-77.
73. Prasugrel 5-mg in the very elderly is non-inferior to prasugrel 10-mg in non-elderly patients: The
GENERATIONS trial, a pharmacodynamic and pharmacokinetic study in stable coronary artery
disease patients.
David Erlinge, MD, PhD1; Paul A. Gurbel, MD 2; Stefan James, MD, PhD3; Tomas L.Lindahl, MD, PhD4;
Peter Svensson, MD, PhD5; Jurrien M. Ten Berg, MD, PhD6; David P.Foley, MBBCh, PhD, FRCPI7; Henrik
Wagner, MD1; Patricia B. Brown, BSN,RN8; Junxiang Luo, PhD8; Chunmei Zhou, MS8; Brian A. Moser,
MS8; Joseph A. Jakubowski, PhD8; David S. Small, PhD8; Kenneth J. Winters, MD8; Dominick J. Angiolillo,
MD, PhD, Accepted maj 2013 JACC
Received 10 October 2012; received in revised form 11 April 2013; accepted 7 May 2013. published online 10 June
2013.
74. Atrial fibrillation patients do not benefit from acetylsalicylic acid.
Sara Själander, MD. Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden.
Anders Själander, MD, PhD. Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden.
Peter J Svensson, MD, PhD. Department for Coagulation Disorders, University of Lund, Malmö, Sweden.
Leif Friberg, MD, PhD. Karolinska Institute and Department of Cardiology, Danderyd University Hospital, Stockholm,
Sweden. Accepted September 2013
2016-02-17
11 (8)
2. Papers under editorial considerations in international journals
1.
The effect of CYP2C19 gene polymorphisms on pharmacokinetics and pharmacodynamics of prasugrel 5-mg,
prasugrel 10-mg and clopidogrel-75 mg in patients with coronary artery disease
Gurbel CYP2C19 genetics in GENERATIONS and FEATHER
Paul A. Gurbel, MD, PhD1; Thomas O. Bergmeijer, MD2; Udaya S. Tantry, PhD1; Jurrien M. Ten Berg, MD, PhD 2;
Dominick J. Angiolillo, MD, PhD 3; Stefan James, MD, PhD 4; Tomas L. Lindahl, MD, PhD 5; Peter Svensson, MD,
PhD 6; Joseph A. Jakubowski, PhD7; Patricia B. Brown, BSN, RN7; Suman Duvvuru, PhD7; Scott Sundseth, PhD8;
Joseph R. Walker, MD9; David Small, PhD7; Brian A. Moser, MS7; Kenneth J. Winters, MD7; David Erlinge, MD,
PhD 10
2.
Interrater reliability and agreement of scoring rubric for assessment of scientific writing in a
medical student program.Eva Ekvall HanssonPeter J SvenssonEva Lena Strandberg Margareta Troein
Töllborn Anders Beckman
3
Atrial fibrillation patients do not benefit from acetylsalicylic acid.
Sara Själander, MD. Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden.
Anders Själander, MD, PhD. Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden.
Peter J Svensson, MD, PhD. Department for Coagulation Disorders, University of Lund, Malmö, Sweden.
Leif Friberg, MD, PhD. Karolinska Institute and Department of Cardiology, Danderyd University Hospital,
Stockholm, Sweden.
4.
Red cell distribution width and risk for first hospitalization due to venous
thromboembolism: a population-based cohort study
Zöller B, Mellander O, Svensson P, Engström G
5
Transforming growth factor (TGF)-β levels and unprovoked recurrent venous
thromboembolism
Ashfaque A. Memon, MD, PhD; 1 Kristina Sundquist, MD, PhD1,2; Xiao Wang, MD,
PhD1,; Peter J. Svensson, MD, PhD3,4; Jan Sundquist, MD, PhD1,2; Bengt Zöller, MD,
PhD1
6
Apolipoprotein M and the risk of unprovoked recurrent venous thromboembolism
2016-02-17
12 (8)
Ashfaque A. Memon1*, Jan Sundquist1, Bengt Zöller1, Xiao Wang1, Björn Dahlback2,
Peter J. Svensson3, Kristina Sundquist1
7
Inflammatory plasma markers and risk for venous
thromboembolism" Signy Vala Sveinsdottir, M.D.; Peter J
Svensson; Gunnar Engström
8
Incidence of thromboembolism, major bleeding and mortality in patients with mechanical heart
valves.
Ashkan Labaf, MD1; Bartosz Grzymala-Lubanski, MD2; Martin Stagmo, MD PhD1; Susanna Lövdahl,
MSc3 Mattias Wieloch, MD PhD4; Anders Själander, MD PhD2; Peter J Svensson, MD PhD5
3. Invited Reviews
1.
Jönsson K-Å, Lagerstedt C, Löwgren B, Mattiasson I, Olsson C-G,
Svensson P, Torstensson I
Venös tromboembolism – Vårdprogram i Södra sjukvårdsregionen. Regionala
koagulationsgruppen 2003. www.medforsk.mas.lu.se/koag.
2.
Svensson P
Profylax mot och reversering av blödning orsakad av antivitamin-K (AVK)läkemedel – Bakgrundsdokumentation. Information från Läkemedelsverket
1:2006.
3.
Svensson P - som deltagare i expertgruppen för
behandlingsrekommendationer AVK-läkemedel
Profylax mot och reversering av blödning orsakad av antivitamin-K (AVK)läkemedel – Behandlingsrekommendation. Information från Läkemedelsverket
1:2006.
4.
Bergström O, Elf J, Gottsäter A, Jonson B, Nilsson C, Nyman U, Olsson
C-G, Stjärnborg-Elofsson C, Svensson P, Torstensson I
Venös tromboembolism - Vårdprogram i Södra sjukvårdsregionen.
Koagulationsrådet i Södra sjukvårdsregionen på uppdrag av
Regionvårdsnämnden 2006. www.medforsk.mas.lu.se/koag.
5.
Dahlman M, Rosberg L, Timberg I, Lindén E, Svensson P,
Torstensson I, Zöller B
Antikoagulationsmottagningar i Södra sjukvårdsregionen - Vårdprogram för
Antikoagulationsmottagningar i Södra sjukvårdsregionen. Koagulationsrådet i
Södra sjukvårdsregionen på uppdrag av Regionvårdsnämnden 2006.
www.medforsk.mas.lu.se/koag.
2016-02-17
13 (8)
6.
Svensson P
Thrombophilia-A clinical approach to thrombophilia testing. In: Klinisk
Biokemi i Norden, Special issue Coagulation 2008;68-71.
7.
Svensson P
Behandling med antikoagulantia. In: Hjärtfel och klaffel – vetenskapligt
underlag för Nationella riktlinjer för hjärtsjukvård 2008 (Socialstyrelsen). Edita
Västra Aros, Västerås 2008;35-8.
8.
Svensson P
Förmaksflimmer och fladder. In: Arytmier – vetenskapligt underlag för
Nationella riktlinjer för hjärtsjukvård 2008 (Socialstyrelsen). Edita Västra Aros,
Västerås 2008;22-7.
9
Svensson PJ
Venous thromboembolism and cancer: what is the link? A clinical approach to
cancer and thrombosis. Oncology 2008;13(3):2-8.
10. Marika Bajc, Olle Bergström, Johan Elf, Anders Gottsäter, Camilla Nilsson
Ulf Nyman, Catharina Stjärnborg-Elofsson , Peter Svensson , Stefan Thörn
Venös tromboembolism Vårdprogram för Södra sjukvårdsregionen 2009 april
11. Hemostas vid allvarlig blödning, Vårdprogram utarbetat av arbetsgrupp
inom Svenska Sällskapet för Trombos och Hemostas (SSTH)
P. Svensson deltagit i denna arbetsgrupp. 2010
2016-02-17
14 (8)
Scientific papers published in national journals
1. Dahlbäck B, Svensson PJ
Nyupptäckt rubbning i antikoagulationen. Resistens mot aktiverat protein C orsak till trombos.
Läkartidningen 1994;91:50-53.
2. Svensson P, Lethagen, Lindén E, Berntorp E
Poliklinisk behandling utan komplikationer. Ett års erfarenheter vid distal djup ventrombos.
Läkartidningen 1994;91:2950-52.
3. Berntorp E, Svensson P, Zöller B, Lethagen S, Dahlbäck B
Resistens mot aktiverat protein C. Vanlig genetisk riskfaktor för venös trombos.
Läkartidningen 1995;92:3587-90.
4. Tödt T, Jedlinska B, Svensson P, van Western D, Hansen O
Lungemboli som orsak till lungödem.
Svensk Cardiologi 1997.
5. Svensson P, Berntorp E
Venös tromboembolism.
Primärvårdens Nyheter 1999; 5: 42-59.
6. Svensson PJ, Follrud C, Thulin L, Berntorp E.
Nytt system testar den mekaniska hjärtklaffen. Egenkontroll i hemmet av antivitamin K-terapin
ger patienten större frihet.
Läkartidningen 1999;96:2478-82.
7. Svensson P, Larsson T, Persson J
Praktik och undervisning förbereder utländska läkare inför kunskapsprov. Erfarenheter i
samverkan med Arbetsförmedlingen i Malmö under 1 års tid.
Socialmedicinsk tidskrift 2000; 1:1-5.
8. Svensson PJ
APC-resistens kan orsaka förlust av transplanterad njure vid akut vaskulär rejektion.
Läkartidningen 2000; 97: 3578.
9. Svensson P, Lindgren S
Varför skall man genomgå specialistexamination i internmedicin?
Internisten 2000;4:8-10.
10.
Svensson PJ
Examination i Internmedicin – ett minne för livet.
Internisten 2001;3:16-20.
2016-02-17
15 (8)
11. Svensson P, Sandberg G, Helldén A, Al Falahe N
Slutrapport från Implementeringsgruppen för invandrade läkare – I-FIL.
Svergies Läkarförbund 2000
12. Svensson PJ, Blomqvist P, Brizzi M, Lanbeck P, Brukwall PS, Larsson T
De första 60 minuterna på akutrummet – multidisciplinär kurs i akutmedicin / trauma baserad
på casemetodik / The first 60 minutes in the emergency room – a multidisciplinary course in
emergency medicine based on a problem-based interactive learning concept.
Läkartidningen 2002;90:4490-2.
13. Svensson P
Internmedicinsk examination – ett kliniskt kunskapstest som avslutning på en klinisk
utbildning
Internisten 2002;3:8-9.
14. Svensson P
Internmedicinsk vardag – testa dina kunskaper del 2
Internisten 2002;3:16-18.
15. Svensson PJ
Låt Waran-patienter ta kontrollen själva.
Landstingsvärlden 3/2003
16. Svensson P, Själander A
Blodpropp - förebyggande diagnostik och behandling av venös tromboembolism.
Internisten 2003;1:6-9.
17. Svensson P
Peroral trombinhämning ett nytt behandlingsalternativ till traditionell antikoagulationsterapi –
en framtida möjlighet
Kärilet 2003;4:4-8.
18. Eriksson H, Hellgren M, Lärfars G, Stigendal L, Svensson P
Venös tromboembolism – fallbeskrivningar från den kliniska vardagen.
ISBN 91-974368-6-0.
19. Svensson P
Protaminsulfat. LEO Pharma 2007.
20. Svensson P
Bred och aktuell – gott komplement på akuten.
Läkartidningen 2007; 104: 361
(Recention av Matell- Reichards Akutmedicin ISBN 91-44-03909-3)
21. Svensson P
Ocplex Protrombinkomplexkoncentrat – Doseringsrekommendationer. Octapharma 2007.
2016-02-17
16 (8)
22. Gøtze Jens Peter, Svensson Peter J, Trombosbehandlingens längd bör ej styras
av D-dimer, Läkartidningen 2007; 11: 851
23. Själander A, Jansson J-H, Bergqvist D, Eriksson H, Svensson P
Evidens för trombosprofylax till medicinpatienter med hög risk. Läkartidningen 2007;2021(104):1585-7.
24. Själander A, Wallentin L, Rosenqvist M, Svensson P
Blodproppshämmande behandling vid förmaksflimmer – bakgrund till nya rekommendationer
och behandlingsalternativ. Läkartidningen 2008;37(105):2478-80.
25. Svensson P, Radulovic V, Holmström M
PCC inom akutsjukvård (Ocplex, protrombinkomplexkoncentrat). Patientfall &
behandlingsrekommendationer. Octapharma 2008.
26. Radolovic V, Svensson P, Hillarp A, Berntorp E
Blödningstidsbestämning har spelat ut sin roll. Läkartidningen 2008;105(17-18):1278-83.
27. Själander A, Hansson LD, Hillarp A, Bergqvist D, Tengborn L, Svensson P
Trombocytopeni kan vara HIT. Heparinbehandling kan ge livshotande låga trombocytvärden.
Läkartidningen 2009;10(106):682-5
28. Själander A, Berntorp E, Svensson P
Principer att reversera warfarin i akuta blödningssituationer – använd inte plasma! Accepted
Läkartidningen 2009.
29. Darwiche G, Svensson P
ABC 60 minutes. Accepted Incitament 2009.
30. Holmström Patrik, Rosenqvist Mårten, Svensson Peter J.
Auricula: förmaksflimmerregistret. Vasculär Medicin; 2009; 3: 139-140
31. Peter J Svensson
Efter 60 år med hepariner och warfarin, Dags för nya perorala antikoagulantia
Läkemedelsbulletinen (Region Skåne), 2009; 8:1-3
32. Svensson P, Radulovic V, Holmström M
PCC inden for akut behandling. Patienttilfaelde og behandlingsrekommandotioner (danska).
Octapharma 2009.
33. Anders Själander, Anna Missios, Elsa Mulugeta , Therese Wetterlöv, Peter J Svensson.
Trombosutredning, -bara när patienten har nytta av resultatet
Läkartidningen 2010; 10: 679-681
34. Signy V. Sveinsdottir, Andreas Hillarp, Jan Astermark1, Peter J. Svensson, Erik
Berntorp
Von Willebrands sjukdom: från biokemi till klinisk praxis. Läkartidningen 2010; 107: 19231927.
2016-02-17
17 (8)
35. Jönnson K, Sterner G, Svensson PJ. Sänkt njurfunktion en riskfaktor vid förmaksflimmer.
Dialäsen 2010; 4: 12-14
36. Anders Själander, Anders Jeppsson, Peter J Svensson
Riktlinjer för behandling med antikoagulantia vid klaffprotes.
Läkartidningen 2010; 107: 2326-2328
37. Peter J Svensson
Klinisk sannolikhetsbedömning och biokemiska trombosmarkörer vid misstanke om djup
ventrombos. Incitament 2010; 19; 366.
38. Karin Knobe, Jan Astermark, Erik Berntorp. Andreas Hillarp. Karin Strandberg, Peter J
Svensson Ovanliga ärftliga former av blödarsjuka Blödningssymtom, familjehistoria och
laboratorieanalyser ger diagnosen. Läkartidningen 2011; 108: 1819-1823.
39. Inger Ros (ordförande Hjärt Lungsjukas förening) Kurt Boman, Tomas Lindahl, Mårten
Rosenqvist, Lennart Stigendal. Hjärtsjuka måste få testa sig själva.
SvD Opinion, 2011-12-24
40. Antikoagulation, nya perorala – åtgärder vid blödning och medicinska ingrepp
Docent Överläkare Anders Själander, Umeå universitet, medicinkliniken Sundsvalls sjukhus
Professor Överläkare Peter J Svensson, Koagulationscentrum SUS Malmö Lunds Universitet
Internetmedicin (www.internetmedicin.se) 2012-02-27
41. Sydsvensk Antikoagulationsvård under revisionsluppen - En välfungerande verksamhet som
kan bli ännu bättre. Läkartidningen 2012; 109: 1411-1
Timberg I, Schedvin G, Svensson PJ
42.
Hur kan effekten av fortbildning värderas? Erfarenheter från en IPULS-certifierad kurs med 5
års uppföljning Socialmedicinsk Tidskrift 2012; 4-5; 121-133, Svensson PJ, Berntorp E
43. TEG och ROTEM – patientnära och snabba koagulationsanalyser minskar transfusionsbehovet
vid lever-och hjärtkirurgi, men frågetecken finns. Zetterberg E, Svensson PJ, Läkartidningen
2013; 110 ( 27-28); 1276-1277
44.
Förmaksflimmer Förekomst och risk för stroke. SBU 2013-04-17
45. Peroral antikoagulation – en lisa för patienten men ett gissel för kirurgen
Anders Själander Peter J Svensson Svensk Kirurgi nummer 2/2013 årgång 71; 92-96
2016-02-17
18 (8)
Correspondandens
1.
Holm J, Zöller B, Svensson PJ, Berntorp E, Erhardt L, Dahlbäck B
Myocardial infarction associated with homozygous resistance to activated
protein C.
Lancet 1994; 344: 952-53 (Letter).
Meeting reports
1. 1 Svensson P
7 PCC in clinical practice for warfarin reversal. Proceedings of the Latvian
. Academy of Sciences 2008;4/5 Suppl (62):S147-9.
Text books
1. Erlinge D, Svensson PJ
Blödningskomplikation vid blodförtunnande behandling – primum non nocere.
In: Kärlsjukdomar – lärobok i medicinsk angiologi. Eds Lindgärde F, Thulin T,
Östergren J. Studentlitteratur 2009
2
Svensson PJ (huvudredaktör), Claudia Mallea Lira, Emma Brücher
Internmedicinsk handbok Studentlitteratur 2010 s 1-530, ISBN; 978-91-4405168-0
3
Svensson PJ, Gottsäter A, huvudredaktörer för boken Venös tromboembolism,
Studentlitteratur,.
PJ Svensson har varit huvudförfattare för 3 av de i boken ingående 29 kapitlen
Studentlitteratur 2010 s 1-384. ISBN 978-91-44-05319-6
4.
Själander A och Peter Svensson
Venös tromboembolism -VTE, Allmänläkarpraktikan; Hjärt-kärlsjukdomar,
Studentlitteratur 2010, 1 kapitel. ISBN 978-91-44-05436-0
Other
1. Thesis
Svensson PJ
Resistance to activated protein C - a novel risk factor for venous thrombosis.
Malmö, Sweden 1997.
Patents
Non.
2016-02-17
19 (8)